Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2001
To the Editor: In their Research Letter about
industry sponsorship of grand rounds, Dr Dieperink and Ms Drogemuller1 suggest "that the increase in quetiapine fumarate
prescriptions was influenced" by a grand rounds sponsored by the manufacturer.
However, they do not prove that this increase was due to the meeting or its
While the authors list several caveats to their study, they do not discuss
3 additional methodological questions. First, was the increase in the prescribing
of the sponsor's drug significantly greater for prescribers who attended the
meeting vs those who did not? The authors could have determined this as they
"had data about prescribing behavior at the individual level." Second, was
any prescribing increase noted for drugs featured in the 51 nonsponsored meetings
vs those not featured at their institution? Third, was there a significant
difference in the prescribing increase for drugs featured in the 20 industry-sponsored
meetings vs the 51 nonsponsored meetings? The authors could have answered
these questions because they "looked at the content and sponsorship of all
presentations" and had a "closed panel of prescribers."
Lohiya G. Effects of Industry Sponsorship of Grand Rounds. JAMA. 2001;286(8):917-918. doi:10.1001/jama.286.8.917-a